Fox Chase prostate cancer expertise helps inform statewide screening discussion

Fox Chase prostate cancer expertise helps inform statewide screening discussion
Daniel M. Geynisman, MD (back row, second from right), Chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, joined Pennsylvania lawmakers, advocates, clinicians, and cancer survivors at the State Capitol in Harrisburg for a legislative briefing on prostate cancer screening held as part of Pennsylvania Prostate Cancer Awareness and Advocacy Day in September.

For Daniel M. Geynisman, MD, the importance of finding prostate cancer earlier is grounded in what he sees in his own clinic at Fox Chase Cancer Center—Temple Health. 

“Part of my job is to meet with men with advanced prostate cancer,” Geynisman told an audience of Pennsylvania lawmakers, advocates, clinicians, and cancer survivors gathered at the State Capitol in Harrisburg on September 29. “Although there are lots of treatments, and better treatments, it is much better to catch it early.” 

That clinical perspective was at the center of a legislative briefing on prostate cancer screening held as part of Pennsylvania Prostate Cancer Awareness and Advocacy Day. The discussion focused on the science of early detection and legislation under consideration in Harrisburg that would eliminate out-of-pocket costs for prostate cancer screening for individuals at increased risk. 

Geynisman is Chief of the Division of Genitourinary Medical Oncology at Fox Chase and editor-in-chief of the Journal of the National Comprehensive Cancer Network. He was invited to the briefing to discuss current evidence-based recommendations for prostate cancer screening. 

A national voice in prostate cancer care 

Fox Chase has played a role in the National Comprehensive Cancer Network (NCCN) since the organization’s beginning as one of its founding member institutions. Today, NCCN includes 34 leading academic cancer centers across the country. 

NCCN’s clinical practice guidelines draw on the expertise of multidisciplinary panels from its member institutions and are continually reviewed as new scientific evidence emerges. The organization’s prostate cancer early detection guidelines recommend beginning screening discussions at age 40 for people at increased risk, including Black men, those with a family history of prostate cancer, and those with certain inherited genetic mutations. 

Geynisman described the value of having evidence-based standards that can help extend high-quality cancer care well beyond the institutions where those guidelines are developed. 

“It democratizes cancer care,” Geynisman said. “Whether you’re getting cancer care in Philadelphia or Pittsburgh or Harrisburg or Anchorage, Alaska, it should be the same for all men.” 

From early detection to advanced prostate cancer 

At Fox Chase, prostate cancer care spans that same continuum. 

Multidisciplinary teams bring together expertise in medical oncology, urologic oncology, radiation oncology, radiology, pathology, genetics, and other specialties to care for patients ranging from those with newly detected or localized prostate cancer to those with advanced disease. 

As chief of Fox Chase’s Division of Genitourinary Medical Oncology, Geynisman specializes in cancers of the genitourinary system, including the treatment of advanced prostate cancer. His comments in Harrisburg reflected both the significant progress that has been made in treating the disease and the opportunity to identify cancers earlier, when treatment options and outcomes can be very different. 

The broader panel included representatives from the American Urological Association, American Cancer Society, ZERO Prostate Cancer, and other organizations, who discussed changes in screening recommendations, the particular importance of screening for people at increased risk, and the growing ability of physicians to distinguish cancers requiring treatment from those that can be carefully monitored. 

Cancer expertise at the capitol 

The briefing was hosted by state Sen. Devlin Robinson and state Rep. Jeanne McNeill, sponsors of legislation addressing insurance coverage for prostate cancer screening. It was part of a day of activities coordinated by a coalition of cancer organizations that included NCCN and the American Cancer Society Cancer Action Network. 

Physicians on the panel discussed how prostate cancer screening has evolved as research has provided a more sophisticated understanding of who is at greatest risk and how patients with abnormal screening results should be evaluated. 

For Geynisman, those advances intersect with the work taking place every day at Fox Chase: identifying prostate cancer earlier when possible while continuing to develop and deliver better options for patients with advanced disease. 

“Although there are more treatments, and better treatments,” he said, “it is much better to catch it early.”